Last reviewed · How we verify

Serine Proteinase Inhibitor WX-671

Heidelberg Pharma AG · Phase 2 active Small molecule

Serine Proteinase Inhibitor WX-671 is a Small molecule drug developed by Heidelberg Pharma AG. It is currently in Phase 2 development. Also known as: MESUPRON.

At a glance

Generic nameSerine Proteinase Inhibitor WX-671
Also known asMESUPRON
SponsorHeidelberg Pharma AG
ModalitySmall molecule
PhasePhase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Serine Proteinase Inhibitor WX-671

What is Serine Proteinase Inhibitor WX-671?

Serine Proteinase Inhibitor WX-671 is a Small molecule drug developed by Heidelberg Pharma AG.

Who makes Serine Proteinase Inhibitor WX-671?

Serine Proteinase Inhibitor WX-671 is developed by Heidelberg Pharma AG (see full Heidelberg Pharma AG pipeline at /company/heidelberg-pharma-ag).

Is Serine Proteinase Inhibitor WX-671 also known as anything else?

Serine Proteinase Inhibitor WX-671 is also known as MESUPRON.

What development phase is Serine Proteinase Inhibitor WX-671 in?

Serine Proteinase Inhibitor WX-671 is in Phase 2.

Related